Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Breast cancer survivors often face numerous challenges during and after treatment, including chemotherapy-induced peripheral neuropathy (CIPN) from neurotoxic antineoplastic treatments. Delayed or underreported CIPN may resul.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056825 | PMC |
| http://dx.doi.org/10.1188/25.CJON.113-118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in gastric cancer patients receiving adjuvant oxaliplatin and capecitabine after gastrectomy: a retrospective pilot study.
Korean J Clin Oncol
August 2025
Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with oxaliplatin-based chemotherapy in gastric cancer patients. Recent studies suggest that high-dose intravenous selenium may exert neuroprotective effects in patients receiving platinum-based chemotherapy.
Methods: This pilot study analyzed patients with stage III gastric adenocarcinoma who underwent gastrectomy between January and December 2024.
Combined Exercise Therapy and Alternating Magnetic Field Therapy for Chemotherapy-Induced Peripheral Neuropathy in a Rectal Cancer Survivor: A Case Report.
Cureus
August 2025
Department of Gastrointestinal Surgery, Panasonic Health Insurance Organization, Matsushita Memorial Hospital, Osaka, JPN.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of several anticancer agents, leading to impaired physical function and quality of life. Although exercise therapy and physical modalities such as transcutaneous electrical nerve stimulation have been reported to alleviate CIPN symptoms, the efficacy of alternating magnetic field therapy remains unclear. We here report a rectal cancer survivor who experienced difficulty returning to work due to persistent neuropathic symptoms of CIPN.
View Article and Find Full Text PDFTrajectory of Chemotherapy-Induced Peripheral Neuropathy and Its Predictive Factors in Breast Cancer Patients: A Prospective Longitudinal Study.
Clin Breast Cancer
August 2025
Tangshan Maternal and Child Health Care Hospital, Tangshan, China. Electronic address:
Objective: To explore the trajectory patterns and influencing factors of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients using latent class growth analysis (LCGA).
Methods: This study was conducted from September 2022 to September 2023 at a tertiary hospital in Tangshan, China. A total of 350 hospitalized breast cancer patients undergoing chemotherapy were recruited.
The Most recent updates on pectin in Cancer therapy: A review.
Int J Biol Macromol
September 2025
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt. Electronic address:
Pectin is a structurally diverse, plant-derived polysaccharide primarily obtained from apple pomace and citrus fruits. Its biocompatibility, modifiability, and multiple bioactivities have attracted increasing interest for potential applications in cancer therapy. This review summarizes modification techniques that enhance pectin's physicochemical and biological properties, elucidates its main anticancer mechanisms, and highlights recent advances (2020-2025) in its therapeutic potential.
View Article and Find Full Text PDFSuppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP (BMX-001).
Oxid Med Cell Longev
September 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University School of Medicine, Durham 27710, North Carolina, USA.
Numerous cellular and animal studies demonstrated the ability of redox-active Mn(III) -alkyl- and -alkoxyalkylpyridyporphyrins (MnPs) to protect normal tissue while suppressing tumor growth. The mechanism primarily involves the modulation of NF-кB and Nrf2 signaling pathways via catalysis of MnP/HO-driven protein thiol oxidation. Such differential protection/suppression effects have paved the way of Mn porphyrins (commonly known as mimics of superoxide dismutase) into clinical trials, therefore introducing new line of therapeutics that are affecting cellular redox status/oxidative stress, rather than specific proteins.
View Article and Find Full Text PDF